Literature DB >> 8338300

Nosocomial outbreaks of multiresistant bacteria: extended-spectrum beta-lactamases have arrived in North America.

A A Medeiros.   

Abstract

Mesh：

Substances：

Year:  1993        PMID： 8338300     DOI： 10.7326/0003-4819-119-5-199309010-00015

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  10 in total

Review 1.  Clinical, bacteriological, and serological aspects of Klebsiella infections and their spondylarthropathic sequelae.

Authors:  H Sahly; R Podschun
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

2.  Spontaneous conversion to quinolone and fluoroquinolone resistance among wild-type Escherichia coli isolates in relation to phylogenetic background and virulence genotype.

Authors:  James R Johnson; Brian Johnston; Michael A Kuskowski; Raul Colodner; Raul Raz
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

3.  Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum beta-lactamase-producing strain of Klebsiella pneumoniae.

Authors:  C Thauvin-Eliopoulos; M F Tripodi; R C Moellering; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

4.  Early diagnosis and therapeutic choice of Klebsiella pneumoniae liver abscess.

Authors:  Jing Li; Ying Fu; Ji-Yao Wang; Chuan-Tao Tu; Xi-Zhong Shen; Lei Li; Wei Jiang
Journal:  Front Med China       Date:  2010-08-17

5.  Detection of extended-spectrum-beta-lactamase-producing members of the family Enterobacteriaceae with Vitek ESBL test.

Authors:  C C Sanders; A L Barry; J A Washington; C Shubert; E S Moland; M M Traczewski; C Knapp; R Mulder
Journal:  J Clin Microbiol       Date:  1996-12       Impact factor: 5.948

6.  Isolation and Characterization of Escherichia coli Sequence Type 131 and Other Antimicrobial-Resistant Gram-Negative Bacilli from Clinical Stool Samples from Veterans.

Authors:  Muhanad Mohamed; Connie Clabots; Stephen B Porter; Paul Thuras; James R Johnson
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

7.  Utilization of an intracellular bacterial community pathway in Klebsiella pneumoniae urinary tract infection and the effects of FimK on type 1 pilus expression.

Authors:  David A Rosen; Jerome S Pinkner; Jennifer M Jones; Jennifer N Walker; Steven Clegg; Scott J Hultgren
Journal:  Infect Immun       Date:  2008-04-14       Impact factor: 3.441

Review 8.  Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors.

Authors:  R Podschun; U Ullmann
Journal:  Clin Microbiol Rev       Date:  1998-10       Impact factor: 26.132

Review 9.  Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  C P Rains; H M Bryson; D H Peters
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

10.  Comparable outcomes for β-lactam/β-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae.

Authors:  Patrick N A Harris; Mo Yin; Roland Jureen; Jonathan Chew; Jaminah Ali; Stuart Paynter; David L Paterson; Paul A Tambyah
Journal:  Antimicrob Resist Infect Control       Date:  2015-05-01       Impact factor: 4.887
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.